All Manufacturers, Suppliers, Distributors and Exporters of Relebactam anhydrous with approved FDA Orange Book of Finished Dosage Form listed on PharmaCompass.com

Relebactam Anhydrous

EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

1 API Suppliers, 1 NDC API, 1 Listed Suppliers

1 API Suppliers
1 NDC API
1 Listed Suppliers

DEVELOPMENTS

2 Drugs in Development

2 Drugs in Development

INTERMEDIATES

6 Intermediates Suppliers

6 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

1 FDF Dossiers, 1 FDA Orange Book

1 FDF Dossiers
1 FDA Orange Book

DIGITAL CONTENT

7 NEWS #PharmaBuzz

media
7 NEWS #PharmaBuzz

PATENTS & EXCLUSIVITIES

3 US Patents, 2 US Exclusivities

patents
3 US Patents
2 US Exclusivities

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 1174018-99-5, Mk-7655, Relebactam anhydrous, Relebactam [inn], (-)-relebactam anhydrous, 1oqf7tt3pf

Molecular Formula

C₁₂H₂₀N₄O₆S

Molecular Weight

348.38 g/mol

InChI Key

SMOBCLHAZXOKDQ-ZJUUUORDSA-N

FDA UNII

1OQF7TT3PF

Relebactam is a diazabicyclooctane beta-lactamase inhibitor, similar in structure to [avibactam]. It includes a piperidine ring which reduces export from bacterial cells by producing a positive charge. It is currently available in a combination product which includes [imipenem] and [cilastatin] to treat complicated urinary tract infections (UTIs), pyelonephritis, and complicated intra-abdominal infections in adults. It is considered to be a last-line treatment option and gained FDA approval as part of the combination product Recarbrio in July 2019.

1 2D Structure

Relebactam

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

[(2S,5R)-7-oxo-2-(piperidin-4-ylcarbamoyl)-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate

2.1.2 InChI

InChI=1S/C12H20N4O6S/c17-11(14-8-3-5-13-6-4-8)10-2-1-9-7-15(10)12(18)16(9)22-23(19,20)21/h8-10,13H,1-7H2,(H,14,17)(H,19,20,21)/t9-,10+/m1/s1

2.1.3 InChI Key

SMOBCLHAZXOKDQ-ZJUUUORDSA-N

2.1.4 Canonical SMILES

C1CC(N2CC1N(C2=O)OS(=O)(=O)O)C(=O)NC3CCNCC3

2.1.5 Isomeric SMILES

C1C[C@H](N2C[C@@H]1N(C2=O)OS(=O)(=O)O)C(=O)NC3CCNCC3

2.2 Other Identifiers

2.2.1 UNII

1OQF7TT3PF

2.3 Synonyms

2.3.1 MeSH Synonyms

1. (2s,5r)-7-oxo-n-(4-piperidinyl)-6-(sulfooxy)-1,6-diazabicyclo(3.2.1)octane-2-carboxamide

2. Mk-7655

3. Mk7655

4. Relebactam Anhydrous

2.3.2 Depositor-Supplied Synonyms

1. 1174018-99-5

2. Mk-7655

3. Relebactam Anhydrous

4. Relebactam [inn]

5. (-)-relebactam Anhydrous

6. 1oqf7tt3pf

7. Chembl3112741

8. Mk-7655a

9. Mk7655

10. Sulfuric Acid Mono-((2s,5r)-7-oxo-2-(piperidin-4-ylcarbamoyl)-1,6-diaza-bicyclo(3.2.1)oct-6-yl) Ester

11. (1r,2s,5r)-7-oxo-2-(piperidin-4-ylcarbamoyl)-1,6-diazabicyclo[3.2.1]octan-6-yl Hydrogen Sulfate

12. [(2s,5r)-7-oxo-2-(piperidin-4-ylcarbamoyl)-1,6-diazabicyclo[3.2.1]octan-6-yl] Hydrogen Sulfate

13. Unii-1oqf7tt3pf

14. Relebactam [mi]

15. Relebactam [who-dd]

16. Bdbm1858

17. Schembl3721178

18. Gtpl10852

19. Ex-a864

20. Sulfuric Acid Mono-[7-oxo-2-(piperidin-4-ylcarbamoyl)-1,6-diaza-bicyclo[3.2.1]oct-6-yl] Ester

21. Bdbm50447651

22. Mfcd28502833

23. Zinc43206319

24. Cs-5391

25. Db12377

26. Ac-36163

27. As-35205

28. Br163749

29. Hy-16752

30. Us8487073, 1a

31. S0074

32. J3.628.086g

33. Mk-7655;mk7655;mk 7655

34. J-690043

35. Q27252695

36. (2s,5r)-7-oxo-n-piperidin-4-yl-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

2.4 Create Date

2009-08-03

3 Chemical and Physical Properties

Molecular Formula	C₁₂H₂₀N₄O₆S
Molecular Weight	348.38 g/mol
XLogP3	-3.6
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	4
Exact Mass	348.11035554 g/mol
Monoisotopic Mass	348.11035554 g/mol
Topological Polar Surface Area	137 Å²
Heavy Atom Count	23
Formal Charge	0
Complexity	585
Isotope Atom Count	0
Defined Atom Stereocenter Count	2
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Relebactam is indicated in combination with [imipenem] and [cilastatin] for the treatment of complicated urinary tract infections (including pyelonephritis), and complicated intra-abdominal infections caused by susceptible organisms in adults.

5 Pharmacology and Biochemistry

5.1 Pharmacology

Relebactam prevents the hydrolysis of [imipenem], allowing it to exert its bactericidal effect.

5.2 MeSH Pharmacological Classification

beta-Lactamase Inhibitors

Endogenous substances and drugs that inhibit or block the activity of BETA-LACTAMASES. (See all compounds classified as beta-Lactamase Inhibitors.)

5.3 Absorption, Distribution and Excretion

Absorption

Currently, relebactam is only available as an intravenous product; therefore, there is no relevant absorption data in the literature.

Route of Elimination

Approximately 90-100% of relebactam is renally eliminated.

Volume of Distribution

Relebactam has a volume of distribution of approximately 19 L with both single and steady state dosing.

Clearance

Relebactam has a reported total clearance of approximately 130-150 mL/min (8 L/h). About 30% of the total drug clearance can be attributed to active tubular secretion.

5.4 Metabolism/Metabolites

Relebactam does not undergo significant metabolism and can be found mostly unchanged in human plasma.

5.5 Biological Half-Life

Relebactam has a half-life of 1.2 hours as per official FDA labeling. Values reported in pharmacokinetic studies vary from 1.35-1.8 hours.

5.6 Mechanism of Action

Relebactam is a beta-lactamase inhibitor known to inhibit many types of beta-lactamases including Ambler class A and Ambler class C enzymes, helping to prevent [imipenem] from degrading in the body. Similar to the structurally-related [avibactam], first, relebactam binds non-covalently to a beta-lactamase binding site, then, it covalently acylates the serine residue in the active site of the enzyme. In contrast to some other beta-lactamase inhibitors, once relebactam de-acylates from the active site, it can reform it's 5 membered ring and is capable of rebinding to target enzymes.

API SUPPLIERS